Objectives. Test the reliability and validity of 5 translations of the 34-item version of the MOS HIV for use in multinational clinical trials.
Research Design. Investigators in five countries followed a standardized protocol and recruited HIV+ patients stratified by disease stage: asymptomatic; symptomatic; and AIDS. During routine clinic visits, patients completed the MOS HIV and a checklist of HIV-related symptoms. Clinicians reported patients' demographics, most recent CD4+ count and disease stage.
Subjects. Three hundred and sixty three HIV+ outpatients attending AIDS clinics in The Netherlands, France, Germany, Italy, and England.
Measures. Dutch, French, German, Italian, and UK English translations of the MOS HIV CD4+ cell count and the SCL-57.
Results. All translations recruited roughly equal proportions of each disease stage, although the number of patients recruited differed by translation (n: German = 92, French = 86; Italian = 88; UK English = 72; and Dutch = 25). Internal consistency reliability was similar across translations and adequate (alpha >.70) for all scales except for Mental Health in the French sample. Multi-trait analyses supported structural validity of the MOS HIV scales in each translation. Principal component analysis of scale scores identified 2 dimensions for all translations except German. For all translations, scores were significantly correlated with symptom severity scores but were uncorrelated with CD4+ cell counts.
Conclusions. In general, the 5 translations of the MOS HIV had similar psychometric properties to those reported in the validation study for the original US English version of the MOS HIV. With some revision, these translations promise to provide useful quality of life data from HIV+ subjects in clinical trials.
*From the Piedmont Research Institute, Inc., Chapel Hill, North Carolina.
†From The School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD.
‡From Global Health Outcomes, Searle, Chicago, Illinois.
§The Health Institute, New England Medical Center, Boston, Massachusetts.
The original study was supported by GlaxoWellcome Inc. Portions of the study results were presented at the 2nd International Conference on AIDS Impact, Brighton, UK, 1994, and the Drug Information Association 2nd Symposium of Contributed Papers on Quality of Life Research, Charleston, SC, 1994.
Address correspondence to: Jane A. Scott-Lennox, PhD, Piedmont Research Institute, Inc., 976 Airport Rd., Suite 100, Chapel Hill, NC 27514.
Received January 20, 1998; initial review completed March 17, 1998; accepted March 18, 1999.